MCID: RLP008
MIFTS: 20

Relapsed/refractory Diffuse Large B-Cell Lymphoma

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Relapsed/refractory Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Relapsed/refractory Diffuse Large B-Cell Lymphoma:

Name: Relapsed/refractory Diffuse Large B-Cell Lymphoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080192

Summaries for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Disease Ontology : 12 A diffuse large B-cell lymphoma characterized by less than 50 percent decrease in lesion size with induction therapy or the appearance of new lesions or the appearance of new lesions after attainment of complete remission.

MalaCards based summary : Relapsed/refractory Diffuse Large B-Cell Lymphoma is related to b-cell lymphomas and diffuse large b-cell lymphoma. An important gene associated with Relapsed/refractory Diffuse Large B-Cell Lymphoma is FOXP1 (Forkhead Box P1). The drugs Cisplatin and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells and endothelial.

Related Diseases for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Diseases related to Relapsed/refractory Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 b-cell lymphomas 10.5
2 diffuse large b-cell lymphoma 10.5
3 lymphoma 10.5
4 mantle cell lymphoma 10.0

Symptoms & Phenotypes for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Drugs for Relapsed/refractory Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 2,Phase 3 15663-27-1 84093 441203 2767
2
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
4
Etoposide Approved Phase 4,Phase 2,Phase 1 33419-42-0 36462
5 BB 1101 Phase 4,Phase 2,Phase 3
6 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
7 Etoposide phosphate Phase 4,Phase 2,Phase 1
8 Endothelial Growth Factors Phase 4
9 Mitogens Phase 4
10 tyrosine Nutraceutical Phase 4,Phase 1,Phase 2
11
Bortezomib Approved, Investigational Phase 2, Phase 3,Phase 1 179324-69-7 387447 93860
12
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
13
Blinatumomab Approved, Investigational Phase 2 853426-35-4
14
Everolimus Approved Phase 2 159351-69-6 6442177
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
17
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
18
Ifosfamide Approved Phase 2,Phase 1 3778-73-2 3690
19
Mesna Approved, Investigational Phase 2,Phase 1 3375-50-6 598
20
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
23
nivolumab Approved Phase 1, Phase 2 946414-94-4
24
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 50-18-0, 6055-19-2 2907
25
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
26
Lenalidomide Approved Phase 1, Phase 2,Phase 2 191732-72-6 216326
27
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
28
Doxorubicin Approved, Investigational Phase 1, Phase 2,Phase 2 23214-92-8 31703
29
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
30
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
31
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
32
Doxil Approved June 1999 Phase 1, Phase 2,Phase 2 31703
33 Antirheumatic Agents Phase 2,Phase 1
34 Antibodies Phase 2,Phase 1
35 Antibodies, Bispecific Phase 2
36 Immunoglobulins Phase 2,Phase 1
37 Alkylating Agents Phase 2,Phase 1
38 Antineoplastic Agents, Alkylating Phase 2,Phase 1
39 Bendamustine Hydrochloride Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 2,Phase 1
41 Antibiotics, Antitubercular Phase 2,Phase 1
42 Antifungal Agents Phase 2
43 Anti-Infective Agents Phase 2,Phase 1
44 Immunosuppressive Agents Phase 2,Phase 1
45 Pharmaceutical Solutions Phase 2,Phase 1
46 Antimitotic Agents Phase 2,Phase 1
47 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
48 Maytansine Phase 2
49 Antibodies, Monoclonal Phase 2,Phase 1
50 Antiemetics Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
2 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Unknown status NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
3 A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03391466 Phase 3 Axicabtagene Ciloleucel;Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
4 A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Unknown status NCT01676558 Phase 2 131I-rituximab
5 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01741792 Phase 2 Blinatumomab
6 Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma Completed NCT01118845 Phase 2 SyB L-0501;Rituximab
7 Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Completed NCT00869999 Phase 2 Everolimus;rituximab
8 Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02391116 Phase 2 Copanlisib (BAY80-6946)
9 Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Completed NCT01470456 Phase 2 SAR3419;rituximab
10 Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT00823719 Phase 2 ofatumumab + ICE;ofatumumab + DHAP
11 AZD1152 in Diffuse Large B-cell Lymphoma Completed NCT01354392 Phase 1, Phase 2 AZD1152
12 Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT02412267 Phase 2 O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
13 To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL Completed NCT02624492 Phase 2 BI 836826;GemOx;Rituximab;GemOx
14 A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting NCT02227251 Phase 2 Selinexor
15 Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT01555541 Phase 2 Ofatumumab;Etoposide;Cytarabine
16 RICE-ibrutinib in Relapsed DLBCL Recruiting NCT02955628 Phase 2 Ibrutinib-RICE
17 Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL Recruiting NCT03305445 Phase 1, Phase 2 Ipilimumab;Nivolumab
18 Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Recruiting NCT01959698 Phase 1, Phase 2 Carboplatin;Carfilzomib;Etoposide;Ifosfamide
19 Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma Recruiting NCT03576443 Phase 2 Idelalisib
20 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations Recruiting NCT02674750 Phase 2 CUDC-907
21 Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients Recruiting NCT03352765 Phase 1, Phase 2 rituximab;bendamustine;melphalan
22 BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) Recruiting NCT03520920 Phase 2 BGB-3111
23 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT02077166 Phase 1, Phase 2 Ibrutinib;Lenalidomide;Rituximab
24 An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma Active, not recruiting NCT02752204 Phase 2 AZD 2014;Rituximab
25 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma Active, not recruiting NCT02142049 Phase 1, Phase 2 Ibrutinib;Part 1: Dose Level 1
26 A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Active, not recruiting NCT02399085 Phase 2 MOR00208;Lenalidomide
27 NM-IL-12 (rHuIL‐12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy Not yet recruiting NCT02544724 Phase 2
28 CyBeR Association in Relapsed/Refractory DLBCL Not yet recruiting NCT02758925 Phase 2 Rituximab;Bendamustine;Cytarabine
29 Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Not yet recruiting NCT03484819 Phase 2 Copanlisib
30 Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Terminated NCT01282476 Phase 2 Panobinostat with Rituximab
31 Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Terminated NCT00978432 Phase 2 RAD001;LBH589;Doublet (RAD001 and LBH589)
32 Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Terminated NCT00968331 Phase 2 Lenalidomide plus Rituximab
33 Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment Terminated NCT00851552 Phase 2 bortezomib;pegylated liposomal doxorubicin hydrochloride
34 Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients Terminated NCT02374424 Phase 2 GA101_DHAP
35 Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment Withdrawn NCT00829205 Phase 1, Phase 2 carboplatin;etoposide;ifosfamide
36 Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma Completed NCT01226849 Phase 1 bortezomib, rituximab, ifosphamide, etoposide, carboplatin
37 Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT03064867 Phase 1 Venetoclax;RICE
38 A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting NCT03255096 Phase 1 RO6870810;Venetoclax;Rituximab
39 A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting NCT03136497 Phase 1 ABT-199;Ibrutinib;Rituximab
40 Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Recruiting NCT03440567 Phase 1 Avelumab;Carboplatin;Etoposide Phosphate;Ibrutinib;Ifosfamide
41 A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. Recruiting NCT02417285 Phase 1 Obinutuzumab;CC-122
42 Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) Recruiting NCT02658968 Phase 1 Betalutin
43 A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Active, not recruiting NCT02220842 Phase 1 Atezolizumab;Obinutuzumab;Tazemetostat
44 Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma Not yet recruiting NCT03450343 Phase 1 Oral azacitidine;R-ICE
45 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Not yet recruiting NCT03571828 Phase 1 AMG 562
46 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Terminated NCT02082977 Phase 1 GSK2816126
47 A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT00301301 Gemcitabine;Cisplatinum;Rituximab
48 Pilot Project for Creation of the Diffuse Large B-cell Lymphoma (DLBCL) Response Prediction Model Recruiting NCT02405078 Not Applicable 18F-fluorodeoxyglucose
49 Axicabtagene Ciloleucel Expanded Access Study Available NCT03153462

Search NIH Clinical Center for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Genetic Tests for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Anatomical Context for Relapsed/refractory Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:

41
B Cells, Endothelial

Publications for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Articles related to Relapsed/refractory Diffuse Large B-Cell Lymphoma:

# Title Authors Year
1
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. ( 29413279 )
2018
2
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( 28060891 )
2017
3
Predictive value of [(18)F]fluoro-2-deoxy-d-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant. ( 23617323 )
2013
4
Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report. ( 23432722 )
2013
5
Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. ( 23813874 )
2013
6
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. ( 23620452 )
2013
7
Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone, and bleomycin in patients with relapsed/refractory diffuse large B cell lymphoma. ( 24070424 )
2013
8
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. ( 23835718 )
2013
9
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. ( 21947824 )
2011

Variations for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Expression for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Relapsed/refractory Diffuse Large B-Cell Lymphoma.

Pathways for Relapsed/refractory Diffuse Large B-Cell Lymphoma

GO Terms for Relapsed/refractory Diffuse Large B-Cell Lymphoma

Sources for Relapsed/refractory Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....